| IPO Company Profile © ipodata.com |
| Message Board | Quote | Chart | News | SEC Filings | Peer IPO Companies |
| First Horizon Pharmaceutical Corporation |
| 660 Hembree Parkway, Suite 106, Roswell, GA 30076 * (770) 442-9707 |
| Business Description | The company is an emerging pharmaceutical company that markets and sells 11 brand name prescription drugs to high-prescribing primary care and select specialty physicians through its nationwide sales and marketing force of 128 professionals. |
| Offering Information Company has | |||
| Trading As | FHRX (NASNTL) | Industry | Pharmaceutical (SIC 2834) |
| Type of Stock Offered | Common Shares | Filing Date | 2/18/00 |
| Domestic Shares Offered | 3,800,000 | Offer Date | 5/30/00 |
| Foreign Shares Offered | 0 | Filing Range | $12.00 - $14.00 |
| Company Shares | 3,800,000 | Offer Price | $8.00 |
| Selling Shrhldrs Shares | 0 | Gross Spread | $0.560 |
| Gross Proceeds | $30,400,000 | Selling | $0.300 |
| Expenses | - - | Reallowance | $0.100 |
| Post-IPO Shares | 12,339,643 | Employees | - - |
| Primary Underwriting Group | ||
| Underwriter Name | Participation | Underwriter Phone |
| Chase H&Q; | Lead Manager | (415) 439-3626 |
| Banc of America Securities LLC | Co-manager | (415) 627-2100 |
| Thomas Weisel Partners LLC | Co-manager | (415) 364-2500 |
| Income Statement and Cash Flow Summary | |||||||
| Prior Audited Income |
Latest Unaudited Income | ||||||
| Full Year Audited Figures | 3 Months Ending | ||||||
| Figures in U.S. millions except per share data | 12/31/95 | 12/31/96 | 12/31/97 | 12/31/98 | 12/31/99 | 3/31/99 | 3/31/00 |
| Revenues | 1.621 | 2.517 | 5.558 | 9.252 | 18.625 | 4.200 | 7.120 |
| Income from Oper. | -0.038 | -0.395 | -0.288 | 0.269 | 1.655 | 0.697 | -0.011 |
| Net Income | -0.092 | -0.344 | -0.180 | 0.136 | 0.770 | 0.376 | -0.039 |
| E.P.S | -0.020 | -0.060 | -0.020 | 0.020 | 0.100 | 0.050 | 0.000 |
| Revenue Growth (%) | 55.28 | 120.84 | 66.47 | 101.301 | 69.52 | ||
| Net Income Growth (%) | - | - | - | 468.38 | - | ||
| Oper. Profit Margin (%) | - | - | - | 2.91 | 8.89 | - | 16.60 |
| Net Profit Margin (%) | - | - | - | 1.47 | 4.14 | - | 8.95 |
| Cash Flow - Oper. | 1.02 | -0.15 | -0.27 | ||||
| Cash Flow - Inv. | -4.19 | -4.08 | -0.07 | ||||
| Cash Flow - Fin. | 2.96 | 3.95 | 0.86 | ||||
| Balance Sheet Summary and Financial Ratios | |||||
| Balance sheet as of: 3/31/00 | Financial Ratios | ||||
| Total Assets | 13.68 | Current Assets | 7.63 | Current Ratio | 0.88 |
| Total Liab. | 10.02 | Current Liab. | 8.64 | Debt Ratio | 73.22% |
| Total Equity | 3.66 | Working Cap. | -1.00 | Debt to Equity Ratio | 2.73 |
| Cash | 0.74 | Return on Assets | 5.63% | ||
| Use Of Proceeds |
The proceeds from the proposed offering will be used to repay debt outstanding under a credit facility with LaSalle Bank, to pay a promissory note with Warner-Lambert, to pay for the purchase of Cognex for general corporate purposes. |
| Legal Counsel Registrar Auditor | |
| Issuer's Law Firm | Arnall Golden & Gregory |
| Bank's Law Firm | Testa, Hurwitz & Thibeault |
| Registrar/Transfer Agent | LaSalle National Trust, N.A. |
| Auditor | Arthur Andersen |
| Send us feedback if you would like to request that we hyperlink a firm on this page | |
| Principal Shareholders | ||
| Name of Shareholder | % Owned Before | % Owned After |
| Kapoor-Pharma Investments, L.P. | 76.00 | |
| Note: represents ownership of 5% or more prior to the offering. | ||